MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
35.74
+2.44
+7.33%
Opening 12:57 10/04 EDT
OPEN
34.23
PREV CLOSE
33.30
HIGH
35.98
LOW
34.22
VOLUME
1.09M
TURNOVER
24.16M
52 WEEK HIGH
104.50
52 WEEK LOW
31.62
MARKET CAP
6.32B
P/E (TTM)
-8.4514
1D
5D
1M
3M
1Y
5Y
Would Exact Sciences Acquire Invitae? Unlikely.
Social media is speculating about the idea that Exact Sciences would buy Invitae. Investors should pinch themselves out of the daydream.
TheStreet.com · 1d ago
YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 5d ago
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Benzinga · 09/27 18:14
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Zacks · 09/27 13:00
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and
Benzinga · 09/23 12:02
Exact Sciences (EXAS) Cologuard Business Grows Amid Cost Woes
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
Zacks · 09/20 15:13
Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) C...
PR Newswire · 09/10 08:33
Exact Sciences (EXAS) Down 25.3% Since Last Earnings Report: Can It Rebound?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/01 15:31
More
About EXAS
Exact Sciences Corporation is a global cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection. It offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. It is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.